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Abstract: The cancer-modelling field is now experiencing a conversion with the recent 
emergence of the RNA-programmable CRISPR-Cas9 system, a flexible methodology to  
produce essentially any desired modification in the genome. Cancer is a multistep process  
that involves many genetic mutations and other genome rearrangements. Despite their 
importance, it is difficult to recapitulate the degree of genetic complexity found in patient 
tumors. The CRISPR-Cas9 system for genome editing has been proven as a robust 
technology that makes it possible to generate cellular and animal models that recapitulate 
those cooperative alterations rapidly and at low cost. In this review, we will discuss  
the innovative applications of the CRISPR-Cas9 system to generate new models, providing 
a new way to interrogate the development and progression of cancers. 
Keywords: CRISPR-Cas9 system; cancer modelling; gene mutations; rearrangements;  
genome engineering 
 
1. Introduction: The Evolution of Cancer Modelling 
Cancer is a multiple-hit disease caused by mutations in genes involved in the control of cell 
function, especially those that control cell growth and division. It enables cells to grow and divide 
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without the need for growth signals and to evade normal checks and balances [1]. Improvements in 
whole-genome sequencing have generated abundant data and detailed sequencing of human cancer 
cells in particular has revealed the complexity of the cancer genome, which undergoes numerous point 
mutations and large genome rearrangements [2,3]. These data must now be converted into functionally 
and clinically relevant knowledge. In this scenario, the generation of cellular and animal models to 
validate new candidate cancer genes and to gain insights into the molecular mechanisms underlying 
tumorigenesis is indispensable. Cancer models have evolved over the years through increasingly 
complex phases, including: (i) cell lines established from human tumors; (ii) xenografts derived from 
explants or cell lines; and (iii) transgenic or endogenous genetically-engineered cell or animal models [4]. 
Genes can be manipulated using several techniques to create genetically-engineered cell or animal 
models. Traditionally, engineered cancer models were obtained by exogenous expression of transgenes 
or manipulation of genes by homologous recombination [5]. During the last ten years, more accurately 
programmable nucleases have been developed for manipulating genomes, thus enabling a more precise 
and sophisticated approach to genetic modelling [6]. These tools include zinc-finger nucleases (ZFNs) 
and transcription-activator-like effector nucleases (TALENs) [7,8]. However, the recent advent of the 
clustered regularly-interspaced short palindromic repeats (CRISPR)-Cas9 system has revolutionized the 
field of cancer modelling. Unlike the genome-editing tools ZFNs and TALENs, which are based on 
sequence recognition via protein–DNA interactions, the CRISPR-Cas9 system can target specific 
genomic loci with a single-stranded guide RNA. Thus, reprogramming of Cas9 is simplified, especially 
taking into account that RNA is much easier to synthesize and to introduce into the cell than protein 
domains. This approach facilitates targeted genome modifications. As mentioned above, CRISPR-Cas9 
relies on the expression of a small guide RNA (sgRNA). When coupled with a Cas9 nuclease, the sgRNA 
can potentially target any locus in the genome by generating double-strand breaks (DSBs) that stimulate 
cellular DNA repair mechanisms, including error-prone non-homologous end joining (NHEJ) and 
homology-directed repair (HDR) [9]. This technique has been adapted to engineer the genome in a wide 
range of experimental models (e.g., human, mouse, rat, zebrafish, fruit fly and rhesus monkey) [10]. The 
CRISPR-Cas9 system can tolerate mismatches in the DNA target with respect to the sgRNA sequence, 
thus potentially promoting damage at off-target sites [11]. However, the combination of pairs of Cas9 
nickase with pairs of sgRNAs prevents this problem from arising [12,13]. 
Cell and animal models are key to increase our understanding of tumor biology [14] and represent 
powerful preclinical platforms for testing of new compounds [15,16]. In this review, we describe  
the novel strategies and mechanisms that have been used to generate CRISPR-Cas9-engineered cancer 
models and highlight key challenges in the application of these sophisticated approaches. 
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Table 1. Overview of the use of the CRISPR-Cas9 system in the context of cancer modelling. HSPC, hematopoietic stem progenitor cells. 
Approach Alteration Target Cell Disease Gene Delivery Reference 
in vitro Loss-of-function mHSPC (mouse) Acute myeloid leukemia (AML) Mll3 Plasmid transfection Chen et al. (2014) [17] 
in vitro Loss-of-function JygMC cell line (mouse) 
Triple-negative  
breast cancer (TNBC) 
Cripto-1 Plasmid transfection Castro et al. (2014) [18] 
in vitro Loss-of-function mHSPC (mouse) Acute myeloid leukemia (AML) 
Tet2, Runx1, Dnmt3a, Ezh2, 
Nf1, Smc3, p53, Asxl1 
LV Heckl et al. (2014) [19] 
in vitro Loss-of-function 
A375 melanoma  
cell line (human) 
Melanoma GeCKO library LV Shalem et al. (2014) [20] 
in vitro 
Loss-of-function  
and directed mutation 
DLD1 and HCT116  
cell lines (human) 
Colon cancer PKC Plasmid transfection Antal et al. (2015) [21] 
in vitro 
Loss-of-function  
and directed mutation 
Organoids intestinal  
epithelium (human) 
Colorectal tumor 
APC, SMAD4, TP53,  
KRAS, PIK3CA 
Electroporation Matano et al. (2015) [22] 
in vitro 
Loss-of-function  
and directed mutation 
Organoids intestinal  
epithelium (human) 
Colorectal tumor APC, SMAD4, TP53, KRAS Electroporation Drost et al. (2015) [23] 
in vitro Gain-of-function 
A375 melanoma  
cell line (human) 
Melanoma SAM library LV Konermann et al. (2014) [24] 
in vitro Chromosomal rearrangement 
HEK293, hMSC,  
hHSPC (human) 
Ewing sarcoma, acute  
myeloid leukemia 
EWSR1-FLI1, RUNX1-ETO Plasmid transfection Torres et al. (2014) [25] 
in vitro Chromosomal rearrangement HEK293 (human) Lung adenocarcinoma 
CD74-ROS1, EML4-ALK, 
KIF5B-RET 
Plasmid transfection Choi and Meyerson (2014) [26] 
in vitro Chromosomal rearrangement HCT116 cell line (human) na NPM1-ALK Plasmid transfection Ghezraoui et al. (2014) [27] 
in vitro Chromosomal rearrangement Myoblasts (mouse) 
Alveolar rhabdomyosarcoma  
(A-RMS) 
Pax3-Fkhr LV Lagutina et al. (2015) [28] 
in vitro Deletion and knock in hESC (human) na TERT Electroporation Chiba et al. (2015) [29] 
in vivo Loss-of-function Lung cells (mouse) Lung adenocarcinoma Nkx2.1, Pten, Apc LV Sanchez-Rivera et al. (2014) [30]   
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Table 1. Cont. 
Approach Alteration Target Cell Disease Gene Delivery Reference 
in vivo Loss-of-function 
Somatic pancreatic cells 
(mouse) 
Pancreatic ductal  
adenocarcinoma (PDAC) 
Lkb1 LV and AdV Chiou et al. (2015) [31] 
in vivo Loss-of-function Cell line (mouse) 
Non-small-cell  
lung cancer (NSCLC) 
GeCKO library LV Chen et al. (2015) [32] 
in vivo 
Loss-of-function  
and directed mutation 
mESCs and zygotes (mouse) na Tet1, Tet2, Tet3, Sry, Uty Injection Wang et al. (2013) [33] 
in vivo 
Loss-of-function  
and directed mutation 
Neurons, immune and 
endothelial cells (mouse) 
Lung adenocarcinoma Kras, p53, Lkb1 
AAV, LV and  
particle-mediated 
delivery 
Platt et al. (2014) [34] 
in vivo 
Loss-of-function  
and directed mutation 








Lung cells (mouse) 
Non-small-cell  
lung cancer (NSCLC) 




Lung cells (mouse) 
Non-small-cell  
lung cancer (NSCLC) 
Eml-Alk AdV Maddalo et al. (2014) [38] 
mHSPC: mouse haematopoietic stem/progenitor cell; LV: lentivirus; hMSC: human primary mesenchymal stem cells; hHSPC: human haematopoietic stem/progenitor cell;  
hESC: human embryonic stem cells; na: not applicable; AAV: adeno-associated virus; AdV: adenovirus. 
 
Int. J. Mol. Sci. 2015, 16 22155 
 
2. Generation of CRISPR Cancer Models 
In order to model the pathogenesis of cancer, it is necessary to efficiently reproduce the complex 
genetic scenario associated with tumorigenesis in specific cell types or organisms [39,40]. Traditional 
experimental approaches used to model the altered genome characteristic of oncogenic cells are 
limited by their complex design and run time. CRISPR is an efficient and accurate tool that has 
facilitated rapid genetic modification and made genetic engineering streamlined and widely applicable, 
both for generating precise human cellular models and for increasing the ease and effectiveness of 
cancer models in other species [41,42] (Table 1). The advances made can improve our understanding 
of cancer biology and facilitate drug screening and the search for new therapies. 
2.1. Modelling Oncogenic Alterations in Vitro 
Human tumor-associated processes have a common major driving force, namely genome  
alterations [43]. Alterations that include large chromosomal rearrangements (i.e., translocations, 
duplications, deletions or inversions) and point mutations lead to inactivation of tumor suppressor genes 
(TSGs), activation of oncogenes and alteration of genes involved in repair processes. CRISPR-Cas9 has 
become the tool of choice for mimicking these scenarios, not only because of its ease of application, but 
also because of its efficiency and accuracy. 
2.1.1. In Vitro Modelling of Chromosomal Rearrangements 
The initial event in the generation of large chromosomal rearrangements is the co-occurrence of two 
DNA double-strand breaks (DSB) in the genome of a cell. Sometimes, the broken ends are recognized 
and repaired by cellular repair machinery to form a rearranged configuration, by which chromosomal 
translocations, deletions, inversions and amplifications are generated. These aberrantly-repaired DNA 
products can act as driver or passenger events in oncogenesis [44]. Different adaptations of the 
CRISPR system have enabled accurate reproduction of large chromosomal rearrangements in vitro by 
means of two sgRNAs targeting the loci involved in a specific genomic event. The CRISPR-Cas9 system 
has considerably improved the efficiency of conventional approaches and ZFNs or TALENs [45]. 
In 2014, our group [29] reported that the adaptation of the CRISPR-Cas9 system to generate targeted 
cancer chromosomal translocations in human cells has paved the way for the generation of cellular 
models that recapitulate the primary oncogenic events driving tumorigenesis. The approach was based 
on a pair of plasmids expressing Cas9 and two sgRNAs that targeted the breakpoints of a cancer 
translocation. We generated and characterized the Ewing sarcoma hallmark t(11;22)/EWSR1-FLI1 
chromosomal translocation in the HEK293 cell line and in human primary mesenchymal stem cells 
(hMSC), with efficiencies of 1.76% and 0.15%, respectively. The aberrant EWSR1-FLI1 transcription 
factor, which is a consequence of the de novo chromosomal translocation, altered the expression of known 
downstream target genes, thus mimicking the effect observed in human tumors. We also demonstrated the 
universalization of this approach by reproducing the acute myeloid leukemia (AML) t(8;21)/RUNX1-ETO 
chromosomal translocation in HEK293 and CD34+ human hematopoietic progenitor cells. Again, 
efficiency was remarkably higher in easily-transfectable established cell lines than in primary cells 
(4.07% and 0.5%, respectively). Almost in parallel, Choi and Meyerson [30] reported the application 
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of the CRISPR-Cas9 system to generate a chromosomal translocation and two inversions involved in the 
development of lung cancer. The authors used a similar approach to mimic the lung adenocarcinoma 
chromosomal translocation t(5;6)/CD74-ROS1 in HEK293 cells and in non-transformed immortalized 
lung epithelial cells (AALE). They also generated two types of inversion events, a paracentric EML4-ALK 
inversion with the breakpoints localized in the short arm of human chromosome 2 and a pericentric 
KIF5B-RET inversion across the two arms of chromosome 10. Both inversions were reproduced separately 
in the HEK293 cell line, yielding an efficiency of 8.9% for the paracentric inversion and 1.62% for the 
pericentric inversion. These and other results [11,29,30] seem to indicate that the adaptation of the 
CRISPR system to reproduce chromosomal rearrangements is clearly dependent on the localization of 
the breakpoints in that efficiency decreases as the distance between the breakpoints increases. This 
approach must be improved upon in order to facilitate the generation of the desired targeted product, 
especially in cases where the rearrangement itself does not confer any growth advantage. 
Ghezraoui et al. used the ZFN, TALEN and CRISPR systems to elucidate the mechanisms of 
genome rearrangements involved in the accumulation of alterations in cancer cells [31]. The authors 
examined the joining mechanism involved in the generation of human chromosomal translocations, 
particularly the role of NHEJ pathways, used either the wild-type CRISPR system or paired Cas9 
nickases to reproduce the t(2;5)/NPM-ALK translocation commonly found in anaplastic large cell 
lymphoma in the modified HCT116 cell line and obtained a targeted translocation efficiency of 0.13%. 
The study concluded that wild-type Cas9 leads to precise joining of the DSBs, whereas paired  
nickase-Cas9 produces insertion/deletions (indels) in the junction regions of the translocation derivative 
chromosomes. This controversial issue could be clarified in the near future using CRISPR combined with 
proper controls and methodologies. 
The CRISPR-Cas9 system can be adapted to generate specific mutations or deletions in non-coding 
or promoter sequences. Chiba et al. [33] used this ability to understand the role of common TERT 
promoter alterations in many neoplastic processes. Using two flanking sgRNAs, the authors were able 
to induce cancer-associated TERT promoter deletions in human embryonic stem cells (hESCs). 
Initially, these changes did not promote any effect in hESCs (no significant difference in telomere 
length was observed compared to control cells). However, upon differentiation into somatic cells, 
which normally silence telomerase, the mutation leads to unsilencing of the telomerase gene, showing 
levels of expression comparable to those of cancer cells and aberrantly long telomeres. 
2.1.2. Modelling Targeted Mutations 
The ability to induce targeted genome modifications in somatic cells empowered the study of gene 
function in several areas of biology, particularly cancer biology. 
In mid-2014, the CRISPR-Cas9 system was used in combination with a short hairpin RNA 
(shRNA) approach to study the role of 7q deletions in promoting leukemogenesis [21]. The authors 
used CRISPR to disrupt the Mll3 gene in mouse hematopoietic stem progenitor cells (HSPC) in an 
Nf1- and p53-deficient genetic context. The analysis of the leukemic cells produced by engineering of 
those genes revealed that they were heterozygous for Mll3, suggesting that leukemogenesis is based on 
partial, but not complete inactivation of Mll3 and supporting the idea that Mll3 is a haploinsufficient 
TSG that may act as a second hit in many AML processes. In September of 2014 [23], the CRISPR-Cas9 
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system was first shown to induce multiple cooperating mutations, thus making it possible not only to 
induce a specific driving genetic mutation, but also to reproduce other secondary associated hits. The 
authors used a combined two-vector lentiviral approach to express CRISPR components in mouse 
HSPCs harboring Flt3-ITD to modify up to five genes ex vivo in a single cell clone. Cooperating  
loss-of-function mutations in genes recurrently inactivated in myeloid malignancies were introduced 
into HSPCs to create AML models. The genes included encoding epigenetic modifiers, transcription 
factors and mediators of cytokine signaling (Tet2, Runx1, Dnmt3, Ezh2, Nf1, Smc3, p53 and Asxl1), 
thus mimicking the genetic combinations observed in patients with AML and leading to myeloid 
clonal expansion and transformation to acute leukemia. In January 2015, the CRISPR-Cas9 system 
enabled Newton, Brognard and coworkers [25] to establish that mutations in protein kinase C (PKC) 
genes generally acted as tumor suppressors, thus modifying previous knowledge and creating a shift 
towards therapies aimed at restoring the altered gene rather than acting against PKC. The authors used 
CRISPR-Cas9 in combination with single-stranded oligodeoxynucleotides (ssODNs) to correct a 
PKCβ gene mutation in a colon cancer cell line (DLD1) from a patient. The correction of the mutation 
restored protein function and reduced tumor size in a xenograft model, thus demonstrating that PKCβ 
confers a growth advantage in this specific tumor environment and has a tumor suppressive function. 
Multiplexing makes it possible to study multiple parameter variations simultaneously and is the 
ideal method for modelling the many changes that take place in cancer. Furthermore, it can be applied 
in a specific cell type, an issue not addressed until recently. During the last two years, several authors 
have reported the use of the CRISPR-Cas9 system to engineer multiple targets simultaneously.  
Matano et al. [26] took advantage of this ability to model colorectal cancer on human intestinal 
organoids. The authors modelled five mutations that promote growth independently of niche signals, 
including TSG (SMAD4, TP53 and APC) and oncogenes (KRAS and PIK3CA). First, to create  
loss-of-function mutations in the human intestinal cells, a vector expressing Cas9 and one sgRNA was 
electroporated in human intestinal stem cells, and different combinations of mutant cell lines were 
obtained using an elegant selection procedure based on the growth advantages of these edited cells  
in medium lacking or containing specific factors [46]. Second, the CRISPR system was used in 
combination with ssODNs to knock in the specific mutations KRASG12V and PIK3CAE545K, and the cells 
were selected again by adding or removing growth factors from the culture medium. This system 
enabled the authors not only to edit five genes in these organoids, but also to obtain single cell clones 
with a different mutational background that recapitulated the adenocarcinoma transition. Two months 
later, Drost et al. [27] published similar results in a study of the same genes,with the exception of 
PIK3CA, in the same cell type (human intestinal organoids). 
2.1.3. CRISPR-Cas9 High-Throughput Genetic Screens 
One of the most promising and exciting applications of the CRISPR-Cas9 system is the option of 
studying gene functions on a genome-wide scale, thus making it a valuable resource for high-throughput 
screening. This advantage has been specifically exploited for the systematic study of genes involved in 
cancer by the generation of sgRNA libraries targeting thousands of genes. 
In 2014, Zhang’s group reported the results of two in vitro studies [24,28] in which a loss-of-function 
library and a genome-wide gain-of-function sgRNA library targeting human genes were used to 
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identify involvement in resistance to vemurafenib, a targeted therapy for melanoma. In the first study, 
the authors used the CRISPR-Cas9 knockout (GeCKO) library, which targets more than 18,000 human 
genes, to test for genes whose loss is involved in resistance to vemurafenib, a BRAF inhibitor, and 
found previously validated genes, as well as new candidates. The second study described the use of a 
sgRNA library targeting all human RefSeq coding isoforms to screen for genes that, upon activation, 
confer resistance to vemurafenib. Using a different approach (activation versus silencing), the authors 
found previously validated and novel candidate genes that confer resistance to the drug. 
More recently, Zhang and Sharp [36] used a genome-wide loss-of-function sgRNA library to 
systematically screen genes involved in metastasis. The authors mutagenized a non-metastatic  
non-small-cell lung cancer cell line derived from a mouse using the GeCKO library described above. 
The mutant cell pools were transplanted into mice and generated tumors. After deep sequencing, a set 
of genes consistently represented in all of the tumors produced was found to be involved in tumor 
growth and metastasis. 
2.2. Modelling Oncogenic Alterations in Vivo: Editing the Genome of Embryonic Stem Cells  
and Embryos 
Highly efficient editing of the genome in a range of experimental models (including mice) can be 
achieved by simple delivery of editing reagents to embryonic stem cells. However, an interesting 
advantage of the CRISPR-Cas9 system over conventional gene targeting technology [47] is that it can 
directly modify the zygote genome, thus saving costs and time in the creation of genetically-modified 
organisms and obviating the need for embryonic stem cells as an essential intermediate. Editing 
reagents can be delivered into the cell in five forms: sgRNAs, as either plasmid or ssRNA; and Cas9 
nuclease, as plasmid, mRNA or protein. Various strategies have been described for the delivery of 
editing reagents, including pronuclear microinjection of the sgRNA/Cas9 plasmid in a manner 
essentially identical to that used for generating transgenic mice or injection of Cas9 mRNA or  
protein directly into the cytoplasm or pronucleus, respectively. The strategies have advantages  
and disadvantages that have to be taken into account when choosing a particular delivery method,  
such as integration of the plasmid in a subset of embryos and differences in survival and targeting 
efficiency [48,49]. Another advantage of the CRISPR-Cas9 system is that it enables simultaneous 
mutation of multiple loci, thus improving the traditional generation of mice carrying mutations in 
multiple genes by sequential recombination of mouse embryonic stem cells (mESCs) or by 
intercrossing of mice with a single mutation. 
In 2013, Wang et al. [37] established three CRISPR-Cas9-based approaches for the generation of 
mice carrying multiple genetic alterations. The first involved co-transfection of mESCs with pooled 
constructs expressing Cas9 and sgRNAs. This strategy enabled the induction of multiplexed gene 
depletion. In the first round of experiments, 20.8% of the clones tested showed mutations in the six 
alleles of the Tet1, 2 and 3 genes. The authors then tried to knock out five genes (Tet1, 2, 3, Sry and 
Uty) and reported that 10% of the clones had a depletion in eight alleles of the five genes. In the 
second approach, the authors directly modified mouse embryos by injecting Cas9 mRNA and sgRNAs 
into the fertilized egg. Co-injection of Cas9 and a single sgRNA for the Tet1, 2 or 3 genes into zygotes 
led 89% of mice to carry indel mutations in a single gene. When a combination of two sgRNAs 
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targeting Tet1 and Tet2 were used, 70% of mice born showed indels in both genes. In the third 
approach, the authors generated mutant alleles with predetermined alterations in zygotes by co-injection 
of Cas9 mRNA and sgRNA and single-stranded DNA (ssODNs) with a desired mutation. This 
approach made it possible to generate, in a single step, one or two pre-designed Tet1 and Tet2 point 
mutations in around 60% and 7% of mice, respectively. The study by Wang et al. [37] paved the way for 
systematic genome-engineered mice and was particularly useful in that it enabled the authors to produce 
mice carrying multiple alterations in loci thought to play a role in the genesis of multigenic diseases, 
such as cancer. 
In cases where indels do not disrupt function, such as non-coding genes or regulatory sequences, 
large genomic deletions or inversions are needed. Xiao et al. [40] described the use of TALEN and 
CRISPR to obtain predictable genomic deletions or inversions with sizes ranging from several hundred 
bases to nearly 1 Mb. The injection of Cas9 mRNA and two sgRNAs targeting distal DNA sites of the 
same chromosome in zebrafish embryos yielded animals with a predictable genomic deletion. For the 
first time, the CRISPR strategy made it possible to delete genomic regions containing the dre-mir-126a 
or miRNA cluster Chr.9 in the zebrafish genome (1%–3% of cases). 
2.3. Modelling Oncogenic Alterations in Vivo: Adult Animals 
The generation of genetically-engineered animal models that recapitulate genomic mutations or 
chromosomal rearrangements using classic approaches is expensive and time consuming, since it 
requires embryonic stem cell engineering and mutant animal crossbreeding [50]. Recent studies have 
demonstrated that the CRISPR-Cas9 system can generate sophisticated cancer models targeting the 
somatic cells of adult animals [42]. This method allowed for faster in vivo testing of single genes or 
combinations of genes in different target tissues when used in combination with efficient delivery 
techniques, such as adenoviruses or adeno-associated virus [51]. The advantages of this approach 
include the possibility of targeting several loci to model the effects of cooperative genetic events or of 
using different cancer-relevant mouse genetic backgrounds in the initiation and progression of cancer. 
The first study in which the CRISPR-Cas9 system was successfully used for precise editing of  
the genome of adult somatic cells was published in October 2014 [39]. Xue et al. [39] targeted a single 
gene or a simultaneous combination of two genes in adult mice hepatocytes by delivering a plasmid 
for transient expression of Cas9 and sgRNAs through hydrodynamic tail vein injection. The authors 
used this strategy to create loss-of-function mutations in Pten (4%), p53 (6.4%) or both genes. Three 
months later, all mice inoculated with sgRNAs simultaneously targeting Pten and p53 developed liver 
tumors. These results illustrate that CRISPR is a potent strategy for modelling carcinogenic mutations 
similar to that of traditional genome-edited Cre/loxP controls. The study also reports the induction of 
Pten mutations using the safer off-target CRISPR nickase approach, albeit with lower efficiency (2.7%). 
Finally, the authors demonstrated that co-delivery of a CRISPR expression plasmid targeting the Ctnnb1 
gene and single-stranded DNA could be used to directly induce gain-of-function mutations via homologous 
recombination in vivo with 0.5% efficiency. 
Another approach for multigene interactions was described by Platt et al. [38], who generated  
a Cre-dependent Cas9 mouse by inserting a floxed-stopped Cas9 expression cassette into the Rosa26 
locus. The first step was to demonstrate that the constitutive or tissue-specific expression of Cas9 
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produced no adverse effects in the mouse. The authors then induced consecutive multiple genetic 
lesions in the same Cre-dependent Cas9 mouse by intranasal or intratracheal delivery of a single 
serotype9 adeno-associated virus (AAV) for the expression of the three sgRNAs, an HDR donor 
template with the KrasG12D mutation and Cre recombinase. Multiplex sgRNA delivery was used to 
simultaneously target the oncogene Kras and the tumor-suppressor genes p53 and Lkb1. Two months 
post-infection, 100% of the treated animals had generated a spectrum of tumors in the lungs. This 
model enabled closer recapitulation of the accumulation of mutations in lung cancer by the generation 
of the KrasG12D mutation and knock-out of p53 and Lkb1 genes in the Cre-dependent Cas9 mouse. 
Blasco et al. [41] showed the CRISPR-Cas9 system to be a feasible approach not only for the 
generation of gene mutations, but also for in vivo engineering of oncogenic chromosomal 
rearrangements in mice and, potentially, other species. The authors reported the successful induction 
of the Eml4-Alk gene rearrangement found recurrently in non-small-cell lung cancers. Lentiviral 
particles were used for intratracheal or intrapulmonary inoculation of the CRISPR components to adult 
mouse lung tissue. The Eml4 and Alk genes, both of which are localized in mouse chromosome 17, 
were targeted by two sgRNAs inducing two DSBs in the same chromosome, which, in some cases  
(1.5 rearrangements/106 cells), were repaired by generating a 10-Mb inversion. Almost in parallel, 
Maddalo et al. [42] reported the induction of the same Eml4-Alk inversion in lung somatic cells of 
adult mice. However, the authors used adenoviral-mediated delivery of the CRISPR system by 
intratracheal instillation to deliver Cas9 and sgRNAs targeting the Alk and Eml4 loci in the lungs.  
In both studies, two to three months after inoculation, all mice developed lung tumors expressing  
the Eml4-Alk fusion oncogene and displaying histopathological and molecular features typical of 
ALK-positive human non-small-cell lung cancer. 
Sanchez-Rivera et al. [34] demonstrated the power of combining the CRISPR system with Cre-loxP 
conditional cancer mouse models [34]. The authors generated a lentivirus-based CRISPR approach to 
express Cre recombinase and CRISPR components (sgRNA and Cas9) for rapid functional investigation 
of genes in the context of conditional adult mouse cancer models. As test models, they chose  
genetically-engineered mouse models of lung adenocarcinoma with KrasG12D/+- or Cre-dependent  
p53flox-flox and analyzed the effect of the induction of loss-of-function mutations in Nkx2.1, Pten and 
Apc TSGs upon intratracheal administration of the lentiviral vectors. The results demonstrated that the 
system is highly efficient in vivo, leading to significant histological and pathway-specific differences 
upon deletion of each of those three TSGs in lung tumors. CRISPR is a rapid somatic genome 
engineering platform for functional characterization of putative cancer genes in the context of 
established mouse models. 
Chiou et al. [35] recently reported the generation of a Cre-regulated Cas9 mouse by integration of  
an LSL-Cas9 cassette into the mouse H11 locus. In those mice, Cas9 will only be expressed after 
recombination of the Stop cassette induced by the expression of Cre recombinase. Direct inoculation 
by retrograde pancreatic ductal injection of an adenoviral or lentiviral vector was used to express Cre, 
and a sgRNA was used to target the Lkb1 gene in the pancreas. CRISPR-mediated targeting of Lkb1 
led to rapid tumor growth that phenocopied Cre-mediated genetic deletion of the Lkb1 gene. This 
approach could potentially be used in vivo to inactivate genes of interest in pancreatic cancer without 
the need to generate new mouse alleles. 
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3. Current Challenges and Potential Solutions 
Although CRISPR-Cas9 has been successfully applied to model cancer using many different 
approaches, the system is still subject to technical limitations. One of the main challenges, both in vivo 
and in vitro, concerns delivery of the necessary components to the target cell. Many efforts have been 
made to increase the efficiency of delivery and to broaden its applicability. Since traditional plasmid 
delivery methods were first used [52,53], two additional approaches have evolved: mRNA [54,55] and 
Cas9 ribonucleoproteins (RNP) [56] (in vitro transcribed sgRNA complexed with recombinant Cas9 
protein), which seem to show the most promising results in poorly transfectable cells [57]. However, 
this approach is limited by the fact that it cannot be used in vivo, because RNP cannot be delivered 
with adequate efficiency to target cells in a living organism. Use of viral vectors seems more practical, 
and several attempts have been made in this respect [58–61]. These methodologies reach a broad range 
of cells, especially primary adult stem cells, which are very difficult to modify using other methods. 
Consequently, the combination of a gene-editing tool and delivery method is more powerful, although 
it has to take into account the possible off-target effects derived from the use of both together. In many 
of the studies reviewed here, lentiviruses were the first choice. Lentiviruses are able to reach almost 
any cell type [62,63] and to generate a broad spectrum of approaches in combination with modifying 
enzymes (nucleases, nickases and recombinases [64–66]), meigaialthough they have mutagenic 
potential that is intensified when they are combined with designer nucleases. Adenoviruses have also 
been used [58] and lead to more specific genome editing. However, they are less efficient and difficult 
to apply in vivo. Their widespread use is hampered because they are more difficult to generate than 
conventional lentiviruses. Adeno-associated viruses are one of the most promising alternatives, 
especially owing to their retargeting ability [67], although they do have a major drawback, namely 
their limited packaging size (4.7 kb) [68]. 
The CRISPR-Cas9 system can induce off-target mutations at sites that are highly homologous to  
on-target sites [11,69–72]. Off-target DNA cleavage can cause unwanted genetic changes and/or 
chromosomal rearrangements with unpredictable consequences [11]. This caveat, which is a major concern 
in original in vitro studies, seems less relevant in vivo [73–77]. Further studies are required to fully 
elucidate the side effects of the CRISPR system. 
The studies reviewed in the present article clearly demonstrate the high efficiency of the CRISPR 
system in the modification, repair and deletion of genes using either in vitro or in vivo approaches 
(Figure 1). However, although CRISPR is a promising technique for cell therapies targeting cancer 
genes in humans, its potential has yet to be fully determined. Off-target effects give cause for concern, 
with the result that more in-depth studies must be performed and new strategies tried to ensure that 
only desired genes are edited and that the effects of the use of CRISPR in human somatic cells is 
known. In addition, ethical issues associated with engineering the human germline are sure to play a 
role in the future [78]. Nevertheless, there is no doubt that the potential of CRISPR in human medicine 
more than compensates for the concerns that arise. 




Figure 1. Types of genome-engineering CRISPR-Cas9 system applications to study cancer. 
HDR: homology-directed repair; sgRNA: small guide RNA; NHEJ: non-homologous  
end joining. 
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